Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05797805 · ClinicalTrials.gov registry record · Phase 1
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
A Phase 1 study of Advanced Hepatocellular Carcinoma, sponsored by Iterion Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 178
- Enrollment target
- 8
- Study locations
NCT05797805 is a Phase 1 study of Advanced Hepatocellular Carcinoma that is actively recruiting participants, run by Iterion Therapeutics. The registered enrollment target is 178 participants, above the 76-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (134% higher). The trial reports 8 study locations across 7 states.
The verdict
NCT05797805, a Phase 1 study of Advanced Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Iterion Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 178 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The second part of the study will begin with a brief dose escalation part for each combination (tegavivint plus cabozantinib or tegavivint plus lenvatinib) followed by a combination dose expansion.
Conditions Studied
Interventions
- DRUG Cabozantinib
- DRUG Lenvatinib
- DRUG Tegavivint
Study Locations (8)
Texas
- UT Southwestern - Dallas
- MD Anderson Cancer Center - Houston
California
- City of Hope - Duarte
Florida
- Sylvester Comprehensive Cancer Center - Miami
Illinois
- University of Chicago - Chicago
North Carolina
- Levine Cancer Institute - Charlotte
Washington
- Fred Hutchinson Cancer Center - Seattle
Ontario
- UHN - Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05797805
The ClinicalTrials.gov registry entry for NCT05797805 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 76-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (134% higher). The listed sponsor is Iterion Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.
NCT05797805 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05797805 about?
NCT05797805 is a clinical study titled "A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma". This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The second part of the study will begin with a brief dose escalati...
What is the current status of trial NCT05797805?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2023-09-13. Estimated completion is 2026-06.
What conditions does trial NCT05797805 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma.
What interventions are being tested in trial NCT05797805?
The interventions under investigation include: Cabozantinib (DRUG), Lenvatinib (DRUG), Tegavivint (DRUG).
Who is sponsoring clinical trial NCT05797805?
This trial is sponsored by Iterion Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05797805 being conducted?
This trial has 8 study locations across California, Florida, Illinois, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RECRUITING · Phase 1
-
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
RECRUITING · Phase 1
-
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
ACTIVE NOT RECRUITING · Phase 1
-
Siliphos in Advanced Hepatocellular Carcinoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.